ATPW
NVCR icon

Ashton Thomas Private Wealth’s NovoCure NVCR Stock Holding History

Ashton Thomas Private Wealth’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-173
Closed -$2.96K – 1414
2024
Q2 		$2.96K Buy
+173
New +$3.04K ﹤0.01% 1676

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ashton Thomas Private Wealth's NVCR Position: Q3 2024 in Review

Ashton Thomas Private Wealth sold out of NovoCure (NVCR) in Q3 2024, closing a stake of 173 shares — an estimated $2.96K sold.

Ashton Thomas Private Wealth first reported a position in NVCR in Q2 2024 and held it in 1 quarter. The position peaked at $2.96K in Q2 2024. 224 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

  • Ashton Thomas Private Wealth reported no remaining NovoCure position as of Q3 2024 after selling out during the quarter.
  • Ashton Thomas Private Wealth sold 173 NovoCure shares in Q3 2024, an estimated $2.96K.
  • Ashton Thomas Private Wealth first reported a position in NovoCure in Q2 2024 and held it in 1 quarter.
  • Ashton Thomas Private Wealth's NovoCure position peaked at $2.96K in Q2 2024.
  • 224 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on Ashton Thomas Private Wealth's 13F filing for Q3 2024, filed 5 Nov 2024.